A heparin-rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis.


Journal

Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208

Informations de publication

Date de publication:
29 Apr 2021
Historique:
received: 19 02 2021
accepted: 20 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 26 10 2021
Statut: epublish

Résumé

An endovascular covered-stent has unique advantages in treating complex intracranial aneurysms; however, in-stent stenosis and late thrombosis have become the main factors affecting the efficacy of covered-stent treatment. Smooth-muscle-cell phenotypic modulation plays an important role in late in-stent stenosis and thrombosis. Here, we determined the efficacy of using covered stents loaded with drugs to inhibit smooth-muscle-cell phenotypic modulation and potentially lower the incidence of long-term complications. Nanofiber-covered stents were prepared using coaxial electrospinning, with the core solution prepared with 15% heparin and 20 µM rosuvastatin solution (400: 100 µL), and the shell solution prepared with 120 mg/mL hexafluoroisopropanol. We established a rabbit carotid-artery aneurysm model, which was treated with covered stents. Angiography and histology were performed to evaluate the therapeutic efficacy and incidence rate of in-stent stenosis and thrombosis. Phenotype, function, and inflammatory factors of smooth-muscle cells were studied to explore the mechanism of rosuvastatin action in smooth-muscle cells. Heparin-rosuvastatin-loaded nanofiber scaffold mats inhibited the proliferation of synthetic smooth-muscle cells, and the nanofiber-covered stent effectively treated aneurysms in the absence of notable in-stent stenosis. Additionally, in vitro experiments showed that rosuvastatin inhibited the smooth-muscle-cell phenotypic modulation of platelet-derived growth factor-BB induction and decreased synthetic smooth-muscle-cell viability, as well as secretion of inflammatory cytokines. Rosuvastatin inhibited the abnormal proliferation of synthetic smooth-muscle cells, and heparin-rosuvastatin-loaded covered stents reduced the incidence of stenosis and late thrombosis, thereby improving the healing rates of stents used for aneurysm treatment.

Sections du résumé

BACKGROUND BACKGROUND
An endovascular covered-stent has unique advantages in treating complex intracranial aneurysms; however, in-stent stenosis and late thrombosis have become the main factors affecting the efficacy of covered-stent treatment. Smooth-muscle-cell phenotypic modulation plays an important role in late in-stent stenosis and thrombosis. Here, we determined the efficacy of using covered stents loaded with drugs to inhibit smooth-muscle-cell phenotypic modulation and potentially lower the incidence of long-term complications.
METHODS METHODS
Nanofiber-covered stents were prepared using coaxial electrospinning, with the core solution prepared with 15% heparin and 20 µM rosuvastatin solution (400: 100 µL), and the shell solution prepared with 120 mg/mL hexafluoroisopropanol. We established a rabbit carotid-artery aneurysm model, which was treated with covered stents. Angiography and histology were performed to evaluate the therapeutic efficacy and incidence rate of in-stent stenosis and thrombosis. Phenotype, function, and inflammatory factors of smooth-muscle cells were studied to explore the mechanism of rosuvastatin action in smooth-muscle cells.
RESULT RESULTS
Heparin-rosuvastatin-loaded nanofiber scaffold mats inhibited the proliferation of synthetic smooth-muscle cells, and the nanofiber-covered stent effectively treated aneurysms in the absence of notable in-stent stenosis. Additionally, in vitro experiments showed that rosuvastatin inhibited the smooth-muscle-cell phenotypic modulation of platelet-derived growth factor-BB induction and decreased synthetic smooth-muscle-cell viability, as well as secretion of inflammatory cytokines.
CONCLUSION CONCLUSIONS
Rosuvastatin inhibited the abnormal proliferation of synthetic smooth-muscle cells, and heparin-rosuvastatin-loaded covered stents reduced the incidence of stenosis and late thrombosis, thereby improving the healing rates of stents used for aneurysm treatment.

Identifiants

pubmed: 33926468
doi: 10.1186/s12951-021-00867-8
pii: 10.1186/s12951-021-00867-8
pmc: PMC8086342
doi:

Substances chimiques

Cytokines 0
Polyesters 0
poly(lactic acid-co-epsilon-caprolactone) 0
Rosuvastatin Calcium 83MVU38M7Q
Heparin 9005-49-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

123

Subventions

Organisme : The Outstanding Academic Leaders Program of Shanghai Municipal Commission of Health and Family Planning
ID : 2017BR006
Organisme : National Natural Science Foundation of China
ID : 81571102
Organisme : National Natural Science Foundation of China
ID : 81870911
Organisme : National Natural Science Foundation of China
ID : 81801148
Organisme : Shanghai Municipal Science and Technology Major Project
ID : 2018SHZDZX01
Organisme : CAMS Innovation Fund for Medical Sciences
ID : 2019-I2M-5-008
Organisme : Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy (CN)
ID : SHDC2020CR2034B
Organisme : Clinical Research Plan of SHDC
ID : SHDC2020CR4033

Références

Biomaterials. 2007 Dec;28(34):5009-27
pubmed: 17688939
Molecules. 2019 Feb 26;24(5):
pubmed: 30813599
Atherosclerosis. 1999 Jun;144(2):335-42
pubmed: 10407494
Cardiovasc Radiat Med. 1999 Jan-Mar;1(1):48-54
pubmed: 11272356
J Biomed Mater Res A. 2015 May;103(5):1784-97
pubmed: 25196988
Biomaterials. 2003 Oct;24(23):4181-90
pubmed: 12853248
Neurosurg Rev. 2007 Jul;30(3):177-80; discussion 180
pubmed: 17508225
Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):1960-6
pubmed: 18688017
Acta Biomater. 2017 Sep 15;60:3-22
pubmed: 28716610
Eur Radiol. 2013 Jan;23(1):287-97
pubmed: 22782569
Eur Heart J. 2008 Feb;29(3):402-12
pubmed: 18212388
J Biomech. 2005 Jun;38(6):1221-7
pubmed: 15863106
Platelets. 2016 Jul;27(5):410-9
pubmed: 26765134
J Biomed Mater Res A. 2011 Jun 1;97(3):339-47
pubmed: 21465642
Lancet Neurol. 2014 Jan;13(1):59-66
pubmed: 24290159
Circulation. 1997 Mar 18;95(6):1549-53
pubmed: 9118524
FASEB J. 2005 May;19(7):804-6
pubmed: 15728660
World Neurosurg. 2019 Mar;123:e194-e201
pubmed: 30476668
Nat Rev Neurol. 2016 Dec;12(12):699-713
pubmed: 27808265
J Am Coll Cardiol. 2010 Apr 13;55(15):1553-65
pubmed: 20378071
J Neurosurg. 1992 Oct;77(4):515-24
pubmed: 1527608
AJNR Am J Neuroradiol. 2007 Sep;28(8):1579-85
pubmed: 17846216
J Cardiovasc Transl Res. 2014 Jun;7(4):413-25
pubmed: 24800874
ACS Appl Mater Interfaces. 2018 Dec 5;10(48):41012-41018
pubmed: 30403126
Acta Neurochir (Wien). 2004 Jul;146(7):705-11
pubmed: 15197614
Lancet. 2003 Jul 12;362(9378):103-10
pubmed: 12867109
Adv Healthc Mater. 2021 Feb;10(3):e2000604
pubmed: 33300246
Physiol Rev. 1979 Jan;59(1):1-61
pubmed: 108688
Am J Cardiol. 1988 Oct 1;62(10 Pt 2):3F-24F
pubmed: 2972185
Neurosurgery. 2009 Apr;64(4):632-42; discussion 642-3; quiz N6
pubmed: 19349825
Atherosclerosis. 1995 Dec;118(2):213-21
pubmed: 8770315
Biomed Pharmacother. 2018 Jul;103:844-850
pubmed: 29710500
Rev Esp Cardiol (Engl Ed). 2015 Dec;68(12):1118-24
pubmed: 26206247
PLoS One. 2015 Apr 15;10(4):e0122577
pubmed: 25874930
J Biomed Mater Res A. 2009 Jul;90(1):205-16
pubmed: 18491396
Clin Exp Immunol. 1986 May;64(2):261-8
pubmed: 3527502
Lancet. 2002 Oct 26;360(9342):1267-74
pubmed: 12414200
J Am Coll Cardiol. 2004 Aug 18;44(4):733-9
pubmed: 15312851
Lancet. 2005 Sep 3-9;366(9488):809-17
pubmed: 16139655
Int Heart J. 2019 Sep 27;60(5):1154-1160
pubmed: 31484855
Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1093-9
pubmed: 12117722
Lancet Neurol. 2009 Jul;8(7):635-42
pubmed: 19501022
Circulation. 2003 Jul 8;108(1):37-42
pubmed: 12821546
AJNR Am J Neuroradiol. 2014 Dec;35(12):2326-33
pubmed: 24722307
Vascul Pharmacol. 2015 Jul;70:8-14
pubmed: 25737404
J Control Release. 2019 May 28;302:19-41
pubmed: 30922946
N Engl J Med. 1998 Dec 10;339(24):1725-33
pubmed: 9867550
J Neurol Neurosurg Psychiatry. 2013 Mar;84(3):244-53
pubmed: 23138770
Dis Markers. 2014;2014:237067
pubmed: 25614710
Cell Physiol Biochem. 2017;44(1):215-228
pubmed: 29131001
Neurosurgery. 2008 May;62(5):E1176-7; discussion E1177
pubmed: 18580791
J Long Term Eff Med Implants. 2000;10(1-2):19-45
pubmed: 10947628
J Biomed Nanotechnol. 2013 Mar;9(3):430-40
pubmed: 23620999
J Cell Mol Med. 2001 Oct-Dec;5(4):378-87
pubmed: 12067471
Ann Biomed Eng. 2016 Feb;44(2):523-35
pubmed: 26139297
J Biomed Mater Res A. 2009 Dec;91(3):878-85
pubmed: 19065570
Circulation. 2003 Mar 11;107(9):1265-70
pubmed: 12628946
Science. 1992 Sep 4;257(5075):1357-63
pubmed: 1529336
Biochem Biophys Res Commun. 2006 Oct 6;348(4):1367-77
pubmed: 16919601
J Am Coll Cardiol. 2010 Nov 30;56(23):1897-907
pubmed: 21109112
Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1617-23
pubmed: 12377739
Adv Drug Deliv Rev. 2006 Jun 3;58(3):377-86
pubmed: 16650911
J Neurointerv Surg. 2018 Dec;10(12):1197-1202
pubmed: 29680819
Pharmacol Ther. 1999 Dec;84(3):413-28
pubmed: 10665838

Auteurs

Yingjun Liu (Y)

Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Neurosurgical Institute of Fudan University, Shanghai, China.
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China.
Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, China.

Peixi Liu (P)

Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Neurosurgical Institute of Fudan University, Shanghai, China.
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China.
Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, China.

Yaying Song (Y)

Department of Neurology, Renji Hospital of Shanghai Jiao Tong University, Shanghai, China.
Neuroscience and Neuroengineering Research Center, Med-X Research Institute and School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.

Sichen Li (S)

Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Neurosurgical Institute of Fudan University, Shanghai, China.
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China.
Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, China.

Yuan Shi (Y)

Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Neurosurgical Institute of Fudan University, Shanghai, China.
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China.
Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, China.

Kai Quan (K)

Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Neurosurgical Institute of Fudan University, Shanghai, China.
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China.
Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, China.

Guo Yu (G)

Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Neurosurgical Institute of Fudan University, Shanghai, China.
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China.
Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, China.

Peiliang Li (P)

Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. peiliangli@126.com.
Neurosurgical Institute of Fudan University, Shanghai, China. peiliangli@126.com.
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China. peiliangli@126.com.
Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, China. peiliangli@126.com.

Qingzhu An (Q)

Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. anqingzhu@me.com.
Neurosurgical Institute of Fudan University, Shanghai, China. anqingzhu@me.com.
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China. anqingzhu@me.com.
Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, China. anqingzhu@me.com.

Wei Zhu (W)

Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. drzhuwei@fudan.edu.cn.
Neurosurgical Institute of Fudan University, Shanghai, China. drzhuwei@fudan.edu.cn.
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China. drzhuwei@fudan.edu.cn.
Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, China. drzhuwei@fudan.edu.cn.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH